Ocular Surface Disease

Dupilumab linked to increased risk of ocular surface diseases

Dupilumab use is associated with an increased risk of developing or exacerbating ocular surface diseases (OSD), particularly dry eye, according to a study. Using the FDA Adverse Event Reporting System (FAERS) database, the study identified 85 signals of DIOSD between 2017 and 2023. Dry eye was the most frequently reported...